Augmentin and Nebcin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Augmentin (amoxicillin; clavulanate potassium) and Nebcin (tobramycin sulfate). Common drug interactions include cough among females and chronic kidney disease among males.

The phase IV clinical study analyzes what interactions people have when they take Augmentin and Nebcin. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Augmentin?

Augmentin has active ingredients of amoxicillin; clavulanate potassium. It is often used in sinusitis. eHealthMe is studying from 42,620 Augmentin users. Check the latest studies of Augmentin.

What is Nebcin?

Nebcin has active ingredients of tobramycin sulfate. eHealthMe is studying from 217 Nebcin users. Check the latest studies of Nebcin.

On Jul, 12, 2026

14 people who take Augmentin and Nebcin together, and have interactions are studied.

What are the common drug interactions of Augmentin and Nebcin, by gender? *:

female:

Cough
Cystic fibrosis (disease of the secretary glands)
Decreased appetite
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Headache (pain in head)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
Pyrexia (fever)

male:

Chronic kidney disease
Emotional distress
Weight decreased
Haematoma (collection of blood outside the blood vessels)
Heart rate decreased
Hypotension (abnormally low blood pressure)
Pain
Pneumonia bacterial (pneumonia associated with bacterial infection)
Renal failure (kidney dysfunction)
Respiratory failure (inadequate gas exchange by the respiratory system)

What are the common drug interactions of Augmentin and Nebcin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Pneumonia bacterial (pneumonia associated with bacterial infection)
Respiratory failure (inadequate gas exchange by the respiratory system)
Viral infection
Weight decreased

10-19:

Cough
Cystic fibrosis (disease of the secretary glands)
Decreased appetite
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Headache (pain in head)
Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
Musculoskeletal chest pain (pain in chest muscle or nerve or bones)
Pyrexia (fever)

20-29:

Chronic kidney disease
Emotional distress
Haematoma (collection of blood outside the blood vessels)
Pain
Renal failure (kidney dysfunction)

30-39:

n/a

40-49:

n/a

50-59:

Erythema (redness of the skin)
Rash macular (small, flat red spots)
Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)

60+:

Thrombocytopenia (decrease of platelets in blood)
Bone marrow depression (decreased ability or inability of the bone marrow to produce blood cells)
Death
Drug hypersensitivity
Heart rate decreased
Hypotension (abnormally low blood pressure)
Intestinal resection
Lymphoma (cancer that begins in immune system cells)
Osteomalacia (softening of the bones due to a lack of vitamin d)
Pathological fracture (broken bone caused by disease)

What are the existing conditions these people have? *

Vulvovaginal Candidiasis (vulvovaginal infection by fungi): 3 people, 21.43%
Cough: 3 people, 21.43%
Cystic Fibrosis Lung (fibrosis with cyst in the lung): 3 people, 21.43%
Constipation: 3 people, 21.43%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 21.43%
Hyperglycemia (high blood sugar): 3 people, 21.43%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 3 people, 21.43%
Liver Disorder (liver diseases): 3 people, 21.43%
Nasal Polyps (masses that develop in the lining of the nose): 3 people, 21.43%
Nausea (feeling of having an urge to vomit): 3 people, 21.43%

* Approximation only. Some reports may have incomplete information.

Do you take Augmentin and Nebcin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously